Skip to main content

Author: Bill Snyder

VUMC research ramps up in COVID-19 transition

May. 21, 2020—As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.

Read more


Antibodies eye Pacific Island “fever”

May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

Read more


New method captures early viral-host protein interactions

May. 7, 2020—Researchers have developed a method to identify the primary interactions between incoming viral RNA genomes and host proteins.

Read more


Antibody finding raises hopes for Marburg, COVID-19 treatments

Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection.

Read more


Researchers developing potential coronavirus antibody therapies

Apr. 8, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Read more


Blocking stress-induced relapse

Apr. 8, 2020—Danny Winder and colleagues are teasing apart the actions of neurotransmitter receptors in a brain region linked to anxiety and addiction, with a goal of finding treatments for substance use disorders.

Read more


VUMC team aids development of potential antiviral drug for COVID-19

Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Read more


Triple-negative breast cancer drug therapy shows promise

Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

Read more


Breast cancer study may help predict treatment response

Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

Read more


Potential new heartburn drug studied at VUMC

Feb. 26, 2020—An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.

Read more


Protein interactions and brain function

Feb. 20, 2020—Roger Colbran and colleagues have discovered new molecular details about the function of an enzyme with a key role in shaping learning and memory.

Read more


Post-transplant diabetes may be reversible: study

Feb. 20, 2020—Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.

Read more


VIEW MORE EVENTS >